StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
This year
1
Publishing Date
2024 - 01 - 08
1
2023 - 12 - 11
1
2023 - 08 - 29
1
2023 - 07 - 12
1
2023 - 06 - 12
1
2023 - 05 - 23
1
2023 - 05 - 12
1
2023 - 04 - 26
2
2023 - 03 - 27
1
2022 - 11 - 01
1
2022 - 09 - 19
1
2022 - 06 - 07
1
2022 - 04 - 01
1
2022 - 02 - 01
1
2021 - 09 - 28
1
Sector
Health technology
16
Tags
Agreement
8
Alzheimer's
10
America
67
Antibody
8
Approval
13
Biosimilar
32
Breast
13
Business
9
Cancer
91
Cell
9
Chmp
10
Diabetes
15
Diagnostics
17
Disease
61
Drug
86
Earnings
18
Europe
15
Expansion
11
Expected
35
Eye
15
Fda
23
Financial
24
Global
228
Growing
43
Growth
236
Health
19
Immunotherapy
11
Infection
9
Key
9
Kisqali
11
Leukemia
10
Liver
11
Market
593
N/a
949
Novartis
135
People
13
Pharma
13
Pharmaceuticals
17
Pipeline
12
Positive
16
Potential
10
Reach
34
Report
194
Research
118
Respiratory
11
Results
38
Risk
10
Sales
10
Sclerosis
13
Set
16
Study
15
T-cell
11
Technology
12
Therapeutics
110
Therapy
65
Treatment
114
Trial
16
Update
10
Vaccine
10
Year
12
Entities
Abbvie inc.
2
Aerie pharmaceuticals, inc.
1
Alcon inc.
1
Aldeyra therapeutics, inc.
1
Amgen inc.
2
Astrazeneca plc
1
Autolus therapeutics plc
1
Bausch health companies inc.
1
Chinook therapeutics, inc.
1
Erasca inc
1
Glaukos corporation
1
Grifols, s.a.
1
Icon plc
1
Johnson & johnson
2
Novartis ag
16
Ocular therapeutix, inc.
1
Pfizer, inc.
1
Sangamo therapeutics, inc.
1
Sanofi
2
Teva pharmaceutical industries ltd
1
Symbols
ABB
72
ABBV
32
ABLZF
31
ACHV
21
AIMC
23
ALDX
32
ALPMF
22
ALPMY
22
ARQT
22
ARVL
21
ATHE
26
ATNM
25
AVXL
21
AZN
52
BGNE
23
BIVI
23
BMY
48
BTAI
25
CLSD
22
CNHI
69
CYTK
24
DVAX
23
ENLV
25
EXEL
28
FBIO
29
FDMT
21
FNCTF
66
GIC
37
GILD
23
GTES
25
HCM
22
HON
53
HZNP
35
ICLR
26
IMAB
21
IMMP
25
IMMX
23
IMUX
21
INCY
28
JCI
22
JNJ
99
LLY
116
MBRX
30
MRK
45
NVCR
22
NVO
32
NVS
25
OCGN
23
PDSB
23
PFE
47
PSTV
29
REGN
30
RGNX
27
SLS
23
SNY
166
SNYNF
121
SRNE
33
STAG
32
TAK
36
TMO
28
Exchanges
Nasdaq
16
Nyse
16
Crawled Date
2024 - 01 - 08
1
2023 - 12 - 11
1
2023 - 08 - 29
1
2023 - 07 - 12
1
2023 - 06 - 12
1
2023 - 05 - 23
1
2023 - 05 - 13
1
2023 - 04 - 26
2
2023 - 03 - 27
1
2022 - 11 - 01
1
2022 - 09 - 19
1
2022 - 06 - 07
1
2022 - 04 - 01
1
2022 - 02 - 01
1
2021 - 09 - 28
1
Crawled Time
00:20
1
01:00
1
06:00
2
07:00
1
10:00
1
11:00
2
12:00
1
12:20
1
15:00
3
16:00
2
20:00
1
Source
www.biospace.com
3
www.globenewswire.com
9
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
symbols :
NVSEF
save search
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published:
2024-01-08
(Crawled : 07:00)
- globenewswire.com
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-7.01%
|
O:
0.89%
H:
0.12%
C:
-0.17%
scemblix
leukemia
trial
response
molecular
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Published:
2023-12-11
(Crawled : 01:00)
- globenewswire.com
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
2.66%
|
O:
0.75%
H:
0.55%
C:
0.27%
fabhalta
novartis
trial
results
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Published:
2023-08-29
(Crawled : 12:00)
- globenewswire.com
ERAS
|
$1.93
4.32%
4.15%
440K
|
|
-26.62%
|
O:
0.0%
H:
1.52%
C:
-2.09%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-3.4%
|
O:
-0.18%
H:
1.41%
C:
1.1%
tumors
trial
plus
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
Published:
2023-07-12
(Crawled : 12:20)
- biospace.com/
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
1.75%
|
O:
0.29%
H:
0.49%
C:
0.26%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-9.31%
|
O:
-0.89%
H:
0.0%
C:
0.0%
hope
beacon
education
novartis
trial
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
Published:
2023-06-12
(Crawled : 20:00)
- globenewswire.com
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-1.14%
|
O:
-0.26%
H:
0.15%
C:
-0.42%
KDNY
|
$40.39
0.22%
-0.17%
0
|
Health Technology
|
6.35%
|
O:
-0.21%
H:
0.26%
C:
-0.08%
bion-1301
nephropathy
association
renal
trial
therapeutics
igan
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published:
2023-05-23
(Crawled : 15:00)
- prnewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
13.64%
|
O:
-1.22%
H:
0.0%
C:
-0.62%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-1.87%
|
O:
0.74%
H:
0.0%
C:
-1.22%
GKOS
|
$101.1
2.17%
0.0%
350K
|
Health Technology
|
70.49%
|
O:
-0.71%
H:
2.06%
C:
-1.05%
BHC
|
$8.53
0.95%
0.0%
4M
|
Health Technology
|
-3.07%
|
O:
-2.27%
H:
4.24%
C:
-2.21%
ALC
|
$80.76
0.19%
0.0%
940K
|
Health Technology
|
-1.17%
|
O:
-0.51%
H:
0.02%
C:
-3.25%
ABBV
|
News
|
$169.54
0.98%
-0.91%
4.1M
|
Health Technology
|
17.0%
|
O:
-0.31%
H:
0.26%
C:
-1.34%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-13.41%
|
O:
-0.01%
H:
0.0%
C:
0.0%
OCUL
|
News
|
$5.0
-1.48%
-1.5%
2.3M
|
Health Technology
|
-23.2%
|
O:
4.45%
H:
7.65%
C:
2.21%
GRFS
|
$6.485
2.94%
2.85%
3.4M
|
Health Technology
|
-28.08%
|
O:
0.78%
H:
0.0%
C:
-3.74%
ALDX
|
$3.91
-0.51%
-0.51%
450K
|
Health Technology
|
-59.94%
|
O:
0.0%
H:
2.36%
C:
0.61%
pharma
disease
pipeline
set
eye
trial
Zollinger-Ellison Syndrome (Gastrinoma) Clinical Trial Analysis Report 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries
Published:
2023-05-12
(Crawled : 00:20)
- prnewswire.com
AZNCF
|
News
|
$138.73
-4.19%
3.7K
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
News
|
$70.85
1.03%
1.02%
5.6M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
report
trial
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Published:
2023-04-26
(Crawled : 15:00)
- globenewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
10.34%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-4.98%
|
O:
0.62%
H:
0.0%
C:
-2.04%
breast
asco
cancer
kisqali
novartis
trial
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Published:
2023-04-26
(Crawled : 10:00)
- globenewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
10.34%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
-4.98%
|
O:
0.62%
H:
0.0%
C:
-2.04%
transfusion
novartis
trial
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published:
2023-03-27
(Crawled : 06:00)
- globenewswire.com
PFE
|
News
4
|
$26.32
0.23%
0.0%
24M
|
Health Technology
|
-34.84%
|
O:
0.37%
H:
0.2%
C:
-0.79%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
18.27%
|
O:
6.51%
H:
1.75%
C:
1.4%
kisqali
breast
cancer
novartis
trial
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx® (Secukinumab)
Published:
2022-11-01
(Crawled : 11:00)
- biospace.com/
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
47.11%
|
O:
1.13%
H:
0.0%
C:
0.0%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
21.85%
|
O:
0.47%
H:
0.09%
C:
-0.55%
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-14.2%
|
O:
-0.36%
H:
0.0%
C:
0.0%
bat2306
cosentyx
solutions
biosimilar
trial
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published:
2022-09-19
(Crawled : 06:00)
- globenewswire.com
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
22.58%
|
O:
-0.52%
H:
0.69%
C:
0.62%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
18.34%
|
O:
-0.22%
H:
0.1%
C:
0.05%
biosimilar
trial
positive
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Published:
2022-06-07
(Crawled : 15:00)
- globenewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
27.72%
|
O:
-2.41%
H:
0.65%
C:
0.42%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
11.49%
|
O:
-0.63%
H:
0.0%
C:
0.0%
scemblix
novartis
leukemia
trial
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Published:
2022-04-01
(Crawled : 16:00)
- biospace.com/
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
12.66%
|
O:
-0.64%
H:
0.6%
C:
0.57%
immunology
trial
positive
Non-alcoholic Steatohepatitis Clinical Trials Market Size Worth $4.2 Billion By 2030: Grand View Research, Inc.
Published:
2022-02-01
(Crawled : 11:00)
- prnewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
11.94%
|
O:
3.58%
H:
0.0%
C:
-1.59%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
15.02%
|
O:
2.5%
H:
0.0%
C:
0.0%
ICLR
|
News
|
$306.16
2.76%
2.68%
860K
|
Health Technology
|
15.64%
|
O:
0.89%
H:
0.59%
C:
0.41%
hepatitis
als
trials
research
trial
clinical trials
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published:
2021-09-28
(Crawled : 16:00)
- prnewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
|
17.56%
|
O:
-0.12%
H:
1.77%
C:
-0.99%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
|
19.7%
|
O:
0.16%
H:
0.04%
C:
-0.51%
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-8.28%
|
O:
-0.04%
H:
0.5%
C:
-0.18%
ABBV
|
News
|
$169.54
0.98%
-0.91%
4.1M
|
Health Technology
|
57.39%
|
O:
-0.09%
H:
0.93%
C:
-0.26%
SGMO
|
News
|
$0.5212
2.18%
2.13%
2.3M
|
Health Technology
|
-94.69%
|
O:
-1.12%
H:
0.52%
C:
-2.17%
AUTL
|
$4.5
-1.32%
-1.33%
1.7M
|
Health Technology
|
-37.08%
|
O:
-2.67%
H:
1.27%
C:
-5.48%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
28.36%
|
O:
-0.38%
H:
1.16%
C:
-0.01%
clinical trials
therapy
car-t
trials
trial
t-cell
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.